Health & Fitness
Health and Fitness
Health and Fitness
Sun, April 29, 2012Sat, April 28, 2012Fri, April 27, 2012Thu, April 26, 2012Wed, April 25, 2012Tue, April 24, 2012Mon, April 23, 2012Sun, April 22, 2012Sat, April 21, 2012Fri, April 20, 2012Thu, April 19, 2012Wed, April 18, 2012Tue, April 17, 2012ViroPharma To Release 2012 First Quarter Financial Results On May 1, 2012
Published in Health and Fitness on Monday, April 23rd 2012 at 13:10 GMT by Market Wire
ViroPharma To Release 2012 First Quarter Financial Results On May 1, 2012 -- EXTON, Pa., April 23, 2012 /PRNewswire/ --
ViroPharma To Release 2012 First Quarter Financial Results On May 1, 2012
- Conference Call to Discuss Results to Be Held at 9:00 A.M. -
EXTON, Pa., April 23, 2012 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: [ VPHM ]) first quarter financial results for 2012 are expected to be released on Tuesday, May 1, 2012 before the open of the U.S. financial markets.
The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2012 first quarter financial results and other business.
The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at [ http://www.viropharma.com ]. An audio archive will be available at the same address until May 16, 2012. To participate in the conference call, please dial (800) 874-4559 (domestic) and (302) 607-2019 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI). Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at [ http://www.viropharma.com/Products.aspx ]; the prescribing information for other countries can be found at [ www.viropharma.com ].
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, [ www.viropharma.com ]. The company encourages investors to consult these sections for more information on ViroPharma and our business.
SOURCE ViroPharma Incorporated
[ Back to top ] RELATED LINKS
[ http://www.viropharma.com ]
